COPENHAGEN (Reuters) -Novo Nordisk has launched a new late-stage trial for its experimental next-generation obesity drug candidate, CagriSema, as it tries to reassure the market of its potential after
Novo Nordisk Launches Late-Stage Trial for CagriSema Obesity Drug
COPENHAGEN (Reuters) -Novo Nordisk has launched a new late-stage trial for its experimental next-generation obesity drug candidate, CagriSema, as it tries to reassure the market of its potential after disappointing data from two previous studies.
The Danish company made the announcement in an entry published on
"This study will look at how well CagriSema helps people living with obesity to lose weight and maintain the weight loss long-term," Novo Nordisk said in the entry.
(Reporting by Maggie Fick and Stine Jacobsen; Editing by Kirsten Donovan and Terje Solsvik)
